School of Medical Sciences, Faculty of Medicine, Sydney, NSW, Australia.
The Kirby Institute, Faculty of Medicine, Sydney, NSW, Australia.
Front Immunol. 2021 Sep 27;12:752003. doi: 10.3389/fimmu.2021.752003. eCollection 2021.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have become a major concern in the containment of current pandemic. The variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta) have shown reduced sensitivity to monoclonal antibodies, plasma and/or sera obtained from convalescent patients and vaccinated individuals. Development of potent therapeutic monoclonal antibodies (mAbs) with broad neutralizing breadth have become a priority for alleviating the devastating effects of this pandemic. Here, we review some of the most promising broadly neutralizing antibodies obtained from plasma of patients that recovered from early variants of SARS-CoV-2 that may be effective against emerging new variants of the virus. This review summarizes several mAbs, that have been discovered to cross-neutralize across Sarbecoviruses and SARS-CoV-2 escape mutants. Understanding the characteristics that confer this broad and cross-neutralization functions of these mAbs would inform on the development of therapeutic antibodies and guide the discovery of second-generation vaccines.
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 变体的出现已成为当前大流行控制的主要关注点。这些变体包括 B.1.1.7 (Alpha)、B.1.351 (Beta)、P1 (Gamma) 和 B.1.617.2 (Delta)，它们对从康复患者和接种疫苗的个体中获得的单克隆抗体、血浆和/或血清的敏感性降低。开发具有广泛中和广度的有效治疗性单克隆抗体 (mAbs) 已成为缓解这一大流行病破坏性影响的当务之急。在这里，我们回顾了一些从早期 SARS-CoV-2 变体康复的患者血浆中获得的最有前途的广谱中和抗体，这些抗体可能对新出现的病毒变体有效。这篇综述总结了几种 mAbs，这些 mAbs 已被发现可交叉中和 Sarbecoviruses 和 SARS-CoV-2 逃逸突变体。了解赋予这些 mAbs 广泛和交叉中和功能的特性，将有助于治疗性抗体的开发，并指导第二代疫苗的发现。
